Please login to the form below
TNBC
This page shows the latest TNBC news and features for those working in and with pharma, biotech and healthcare.
Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
TNBC is an aggressive and hard-to-treat subtype of breast cancer, representing around 15% of all breast cancer worldwide, approximately 300, 000 cases every year. ... KEYNOTE-522 is the first large randomised phase 3 study to report a statistically
Latest news
-
New trial data for Keytruda in triple-negative breast cancer
triple-negative breast cancer (TNBC) following a recent US Food and Drug Administration (FDA) rejection in this indication. ... TNBC is an aggressive and hard-to-treat subtype of breast cancer, representing around 15% of all breast cancer worldwide,
-
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
Envisagenics is also developing a potential preclinical therapeutic in-house – ENV-0205 – for the treatment of triple-negative breast cancer (TNBC). ... This programme came from Envisagenics’ identification of a splicing error that occurs in TNBC,
-
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
in a group of heavily pre-treated triple negative breast cancer (TNBC) patients. ... In addition to TNBC, datopotamab deruxtecan is in development for the treatment of a number of tumour types which express the cell-surface glycoprotein TROP2.
-
FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer
or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1. ... with metastatic TNBC with PD-L1 tumour expression.
-
EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer
TNBC is a particularly aggressive type of cancer, and high expression of Trop-2 in particular is associated with poor survival and relapse. ... The ADC was approved by the US Food and Drug Administration (FDA) in April last year for the treatment of
New trial data for Keytruda in triple-negative breast cancer
Biogen and Envisagenics to advance RNA splicing research for CNS diseases
AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
FDA panel votes to keep accelerated approval for Roche’s Tecentriq in breast cancer
EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer
More from news
Approximately 5 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
Trop2 is a transmembrane glycoprotein overexpressed in many epithelial cancer cells, including TNBC.
-
Deal Watch January 2018
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... IMMU-132 has FDA Breakthrough Therapy designation for the treatment of patients with TNBC who have failed prior
Cortellis Drugs to Watch in 2020 report
Deal Watch February 2017
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... trocar. Further, TAVO has already proven to show robust efficacy in difficult-to-treat patient populations, including metastatic melanoma
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital strategist
-
Competitive
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Digital project manager
-
Competitive
-
Digital account director
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- GSK reveals plans for £400m R&D facility expansion in England
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- EU approves bluebird bio’s CALD gene therapy Skysona
- NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The future of work has been just around the corner for some time...
- Investigating the Complexities of the Canadian & Global Health Systems
- Impetus Digital Overview
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Tyson Fury takes on his Invisible Opponent in hard hitting ad for suicide prevention charity Campaign Against Living Miserably
- US pauses shipments of Eli Lilly’s COVID-19 antibody treatment due to variant concerns
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Novo Nordisk signs deal for Prothena's heart drug worth up to $1.2bn
PMHub
Apex.co.uk Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...
Latest intelligence
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
- Virtual Speaker Program: A Customer Story
- Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....
